The Global Cardiac Output Monitor Market size is estimated to register a CAGR of around 5.5% through the forecast period. The market growth is driven by the growing prevalence of cardiovascular diseases along with the introduction of modern non-invasive technologies for cardiac output monitoring. According to the World Health Organization, cardiovascular diseases are the major cause of annual deaths globally. Every year, nearly 30 million people suffer a stroke or heart attack. The American Heart Association estimates that nearly half of the adults in the United States have some type of cardiovascular disease, and approximately 45.1% of the U.S. population will have some form of CVD by 2035.
A cardiac output monitor is a device that measures blood flow through the aorta or on the left chest in order to determine trans-pulmonary flow and give insight into a person’s heart condition. Cardiac output generally is referred to as the volume of blood that is being pumped by the heart. In CVD patients, monitoring of cardiac output is rapidly becoming a vital part of early diagnosis & treatment, as well as a standard of patient care. The monitoring enables the management of heart attacks in sepsis patients. Moreover, the inclusion of cardiac output monitoring in treatments provides helpful insights on the oxygen delivery and volume tissue perfusion. The rise in the number of CVD cases, along with the high adoption of C.O. monitoring devices, will boost cardiac output monitor market share through 2032.
Request a Sample@ https://www.qyresearchmedical.com/sample/119476
The introduction of modern non-invasive technologies in cardiac output monitoring are greatly improved and have become more. Increasing the adoption of minimally invasive and non-invasive cardiac output monitoring devices will further boost cardiac output monitor market revenue share over the analysis period.
The cybersecurity vulnerabilities in medical systems, mainly in devices such as cardiac implantable electronic devices, where the potential for rendering or reprogramming device non-functional still exists, is a concerning issue faced by patients and healthcare facilities. Some 500,000 implantable pacemakers were recalled by the US FDA in 2032 owing to their vulnerability to hacking. This may limit the product adoption rate, thereby hampering industry growth.
On the basis of device type, the non-Invasive product segment is accounted for the majority of the global cardiac output monitor market share and is estimated to garner massive revenues through 2032. The robust growth can be attributed to the ongoing improvements in reading accuracy of the non-invasive technologies. The minimally and non-invasive cardiac output monitoring device segments will continue to grow over the forecast period-driven by-product advancements.
On the basis of application, the hospital segment accounted for the largest share of the cardiac output monitor market and is estimated to contribute significantly to the revenue share through 2032. The growth can be attributed to a plethora of factors, including the growing prevalence of CVD, a rise in the number of patient visits to hospitals for disease diagnosis, the availability of reimbursement, and a significant rise in the number of cardiac implant procedures every year.
In the regional landscape, North America is estimated to be a major regional ground for the cardiac output monitor market due to the presence of key industry players in the region, along with an established and advanced medical infrastructure in the region.
Key players operating in the cardiac output monitor market are Cardinal Health, Inc., G.E. Healthcare, Bracco Imaging S.p.A, Nordion, Inc., Bayer HealthCare Medical Care, Lantheus Medical Imaging Inc., Advanced Medical Isotope Corporation, Alliance Medical, Alseres Pharmaceuticals, Inc., Avid Radiopharmaceuticals, Actinium Pharmaceuticals Inc., Ion Beam Applications S.A., Immunomedics, Inc., Jubilant Pharma, Mallinckrodt Pharmaceuticals, Medi-Radiopharma Ltd., Peregrine Pharmaceuticals, Inc., Siemens Healthcare, Positron Corporation and Triad Isotopes, Inc. These industry players are adopting several strategies such as acquisitions, mergers, collaborations, new product development, and capacity expansion, thereby supporting the overall growth of the market. Moreover, rising investments by the key industry players for the R&D activities will further bolster cardiac output monitor market growth over the analysis period.
New York-based Retia Medical won FDA clearance and announced making available its Argos Cardiac Output Monitor in December 2018, across the United States. The product is ideal for use in the ICU and OR, as it efficiently tracks both fluid and pressor resuscitation.
Segments Covered in the report
This report forecasts revenue growth at a global, regional, and country level, and provides an analysis of the market trends in each of the sub-segments from 2023 to 2032. For ease of understanding the study, has segmented the cardiac output monitor market based on device type, application, and region:
By Device type (Revenue in USD Million; 2023–2032)
- Invasive Devices
- Minimally-invasive Devices
- Non-invasive Devices
Applications Outlook (Revenue in USD Million; 2023–2032)
Regional Outlook (Revenue in USD Million; 2023–2032)
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://www.qyresearchmedical.com/report/checkout/119476/1500
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: